Skip to content
SXTP60 Degrees Pharmaceuticals, Inc.

Earnings

When 60 Degrees Pharmaceuticals, Inc. reports, what it reported each quarter, and how the stock took the results.

19 quarters. Mar 31, 2022 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

10-K due Mar 22 – Apr 9

No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 3 filings.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 22 – Apr 9

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$303.39K
Revenue, change from a year earlier: Q3 2026 −46.7%, Q2 2026 +106.0%, Q1 2026 −0.9%, Q4 2025 +25.6%
Net income
-$1.44M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$233.24K−46.7% vs Q3 2025

Latest results

  1. Q3 2026Nov 16, 2026, during market hours
    Revenue
    $233.24K
    −46.7%
    Net income
    -$2.56M
    N/M
    EPS
    -$0.75
    N/M
  2. Q2 2026Aug 14, 2026, during market hours+1.7%by the close of Aug 14
    Revenue
    $207.90K
    +106.0%
    Net income
    -$2.26M
    N/M
    EPS
    -$0.90
    N/M
  3. Q1 2026May 15, 2026, before the open5.1%by the close of May 15
    Revenue
    $162.09K
    −0.9%
    Net income
    -$2.09M
    N/M
    EPS
    -$1.28
    N/M
  4. Q4 2025Mar 30, 2026, after the close+15.9%by the close of Mar 31
    Revenue
    $303.39K
    +25.6%
    Net income
    -$1.44M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026—Nov 16, 202647 d10-Q$233.24K−46.7%-$0.75—
Q2 2026Jun 30, 2026—Aug 14, 202645 d10-Q$207.90K+106.0%-$0.90+1.7%
Q1 2026Mar 31, 2026—May 15, 202645 d10-Q$162.09K−0.9%-$1.285.1%
FY 2025
Q4 2025derivedDec 31, 2025—Mar 30, 202689 d10-K$303.39K+25.6%—+15.9%
Q3 2025Sep 30, 2025—Nov 13, 202544 d10-Q$437.60K+223.4%-$2.664.0%
Q2 2025Jun 30, 2025—Aug 13, 202544 d10-Q$100.93K−19.2%-$5.012.5%
Q1 2025Mar 31, 2025—May 15, 202545 d10-Q$163.55K+54.8%-$6.254.4%
FY 2024
Q4 2024derivedDec 31, 2024—Mar 27, 202586 d10-K$241.64K+92.3%—+1.1%
Q3 2024Sep 30, 2024—Nov 14, 202445 d10-Q$135.29K+164.3%-$2.926.5%
Q2 2024Jun 30, 2024—Aug 14, 202445 d10-Q$124.97K+109.9%-$21.121.5%
Q1 2024Mar 31, 2024—May 15, 202445 d10-Q$105.67K+515.4%$1.834.5%
Earlier years, FY 2022 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 16, 2026002390
10-QAug 14, 2026001860
10-QMay 15, 2026001058
10-KMar 30, 2026000467
10-QNov 13, 2025002032
10-QAug 13, 2025001009
10-QMay 15, 2025043779
10-KMar 27, 2025003343
10-QNov 14, 2024098195
10-QAug 14, 2024068673

Provenance

ProvenanceData status and checks

60 Degrees Pharmaceuticals, Inc. · CIK 1946563 · Engraved from SEC EDGAR